TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10082501
Drug: Instant coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant coffee (5 cups per day, equivalent to 300 mg caffeine per day)
Study: 2202240
Drug: Antacid (Mylanta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (Mylanta II)
Study: 2202240
Drug: GI cocktail
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GI cocktail (antacid + 15 mL of 2% viscous lidocaine)
Study: 7156248
Drug: L-tryptophan-amitriptyline combination
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan-amitriptyline combination
Study: 27129009
Drug: ASP2151 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2151 (100, 200, or 400 mg daily for 3 days)
Study: 27129009
Drug: ASP2151 (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2151 (1,200 mg as a single dose)
Study: 17179772
Drug: Clindamycin vaginal
Normalized name: clindamycin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin vaginal single-dose cream (CVSDC)
Study: 17179772
Drug: Metronidazole vaginal
Normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole vaginal gel (MVG)
Study: 12428241
Drug: High-Dose D-Penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose D-Penicillamine
Study: 12428241
Drug: Low-Dose D-Penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Dose D-Penicillamine
Study: 2492170
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine solution (0.8 mg/kg)
Study: 31085282
Drug: Upper limb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper limb treatment based on voluntary task‐oriented movements
Study: 28295516
Drug: 5% BPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% BPO gel
Study: 26268495
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy combined with metoprolol
Study: 8320728
Drug: 4-aminopyridine (4-AP)
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4-AP) administered via infusion over 2 hours, with a total escalating dose from 18.0 to 33.5 mg.
Study: 8320728
Drug: Vehicle placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle placebo administered via infusion over 2 hours.
Study: 31173921
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy informed by Acceptance and Commitment Therapy (PACT)
Study: 30326045
Drug: hu3F8 (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: hu3F8 (humanized anti-GD2 antibody) infused intravenously for 30 minutes on Monday, Wednesday, and Friday, with dosage escalation up to 9.6 mg/kg/cycle (approximately 288 mg/m2)
Study: 30326045
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor administered subcutaneously daily from 5 days before infusion through the last day of infusion
Study: 30326045
Drug: Higher dosing
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosing of hu3F8
Study: 18936215
Drug: Cysteine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine intake of 10 mg x kg(‐1) x d(‐1)
Study: 18936215
Drug: Cysteine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine intake of 20 mg x kg(‐1) x d(‐1)
Study: 18936215
Drug: Cysteine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine intake of 30 mg x kg(‐1) x d(‐1)
Study: 18936215
Drug: Cysteine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine intake of 40 mg x kg(‐1) x d(‐1)
Study: 18936215
Drug: Cysteine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine intake of 0 mg x kg(‐1) x d(‐1)
Study: 12578880
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with enalapril or nisoldipine; mean blood pressure of 128/75 mm Hg over 4 years.
Study: 2071809
Drug: Phenylpropanolamine hydrochloride
Normalized name: Phenylpropanolamine Hydrochloride
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine hydrochloride (50 mg a day, increasing to 50 mg twice a day)
Study: 21161222
Drug: Fluid plus
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid plus vasopressin (4 IU bolus and 2.4 IU/h infusion for 5 hours)
Study: 18693827
Drug: Wireless devices
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless devices (PDAs and tablet PCs)
Study: 12042191
Drug: Divalproex (500-2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex (500-2500 mg/day in divided doses)
Study: 9676304
Drug: Electrolyte solution
Normalized name: electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte solution (VE)
Study: 2193836
Drug: Cefetamet 500
Normalized name: cefetamet 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet 500 mg orally twice daily for 7 days
Study: 2193836
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg orally three times daily for 7 days
Study: 25789444
Drug: Water only
Normalized name: Water only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water only (treatment A)
Study: 25789444
Drug: Water +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water + cola (treatment B)
Study: 25789444
Drug: Water +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water + diet cola (treatment C)
Study: 25789444
Drug: Water +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water + cola + diet cola + orange juice (treatment D)
Study: 21332346
Drug: Low-dose NCTD
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose NCTD (0.05 mg/kg/day)
Study: 21332346
Drug: High-dose NCTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose NCTD (0.1 mg/kg/day)
Study: 21332346
Drug: Model group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model group (DN rats without treatment)
Study: 19732995
Drug: Placebo-control group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-control group (with weekly relaxation sessions)
Study: 15497493
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated estrogen (CE)/5 mg medroxyprogesterone acetate (MPA)
Study: 15497493
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol/1 mg norethisterone acetate (NETA)
Study: 11521964
Drug: CLA supplementation
Normalized name: CLA
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLA supplementation (Tonalin capsules providing 3.9 g/d of CLA isomers)
Study: 11521964
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oil (sunflower) supplementation (6 daily capsules of 1 g each)
Study: 7921857
Drug: Esmolol 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 60 mg
Study: 7921857
Drug: Esmolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 40 mg
Study: 7921857
Drug: Esmolol 20
Normalized name: esmolol 20 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 20 mg
Study: 3377947
Drug: Extradural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural diamorphine 5 mg in saline 10 ml with adrenaline 1 in 200,000
Study: 3377947
Drug: Extradural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural diamorphine 5 mg in saline 10 ml without adrenaline (saline group)
Study: 31297513
Drug: Self-assessment using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-assessment using a tablet
Study: 31297513
Drug: Self-assessment using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-assessment using a tablet (for patients aged ≥85)
Study: 31297513
Drug: Self-assessment using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-assessment using a tablet (for caregivers)
Study: 1420749
Drug: Algicon Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algicon Suspension
Study: 6319067
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg every 12 hr)
Study: 21907450
Drug: Curcuminoids (6000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (6000 mg/d in 3 divided doses)
Study: 18184542
Drug: Huannao Yicong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huannao Yicong capsule
Study: 11530030
Drug: Low-dose inhaled
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inhaled fluticasone (88 microg twice daily)
Study: 11530030
Drug: Oral zafirlukast
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral zafirlukast (20 mg twice daily)
Study: 11530030
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from zafirlukast to fluticasone (88 microg twice daily)
Study: 7930305
Drug: Diphenhydramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (50 mg three times daily)
Study: 31980978
Drug: Benzbromarone 50
Normalized name: benzbromarone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone 50 mg
Study: 30219400
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol before primary PCI
Study: 25987198
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for panic disorder
Study: 21486113
Drug: Long-term anticoagulation
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term anticoagulation therapy with warfarin (OAC group)
Study: 21486113
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anticoagulant or antiaggregant drugs)
Study: 11789221
Drug: Composite Salviae
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite Salviae Dropping Pill (CSDP), 10 pills three times a day for 4 weeks
Study: 11789221
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (aspirin and other conservative agents only)
Study: 9095007
Drug: Albuterol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (2.5 mg) every 60 minutes for two doses, interspersed with saline aerosols every 20 minutes
Study: 9095007
Drug: Albuterol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (2.5 mg) every 20 minutes for 2 hours
Study: 8459640
Drug: Primary gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary gastric lesion responded to chemotherapy
Study: 8459640
Drug: Primary gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary gastric lesion did not respond to chemotherapy
Study: 28303753
Drug: FTC/TAF (unboosted
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC/TAF (unboosted third agent)
Study: 28303753
Drug: FTC/TDF (unboosted
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC/TDF (unboosted third agent)
Study: 22562974
Drug: MR prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MR prednisone 5 mg once daily in the evening plus DMARD
Study: 6373441
Drug: Dipyrone 500
Normalized name: dipyrone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 500 mg
Study: 21457066
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (LIS)
Study: 23038415
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.25% levobupivacaine with 5 μg/mL epinephrine
Study: 23038415
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.25% levobupivacaine without epinephrine
Study: 16005438
Drug: Metyrapone (cortisol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (cortisol synthesis inhibitor)
Study: 14564242
Drug: Vecuronium (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (1.3 mg/kg)
Study: 1832944
Drug: TAM (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM (20 mg b.i.d.)
Study: 1832944
Drug: TAM-MPA (TAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM-MPA (TAM 20 mg b.i.d. for 7 days, then TAM plus 500 mg MPA for 7 days)
Study: 3545685
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g per day)
Study: 19021097
Drug: Feeding in
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeding in anemic infants > 1250 g
Study: 17936446
Drug: Live-attenuated influenza
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-attenuated influenza vaccine, trivalent
Study: 11985880
Drug: Creatine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (8 g/day for 5 days)
Study: 10397695
Drug: Recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hirudin (r‐hirudin) 0.35 mg/kg
Study: 8749149
Drug: Loratadine 40
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine 40 mg daily
Study: 6282302
Drug: Medium-fibre coarse-bran
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-fibre coarse-bran bread diet (22 g NDF/d)
Study: 6282302
Drug: High-fibre coarse-bran
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fibre coarse-bran bread diet (35 g NDF/d)
Study: 6282302
Drug: Medium-fibre fine-bran
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-fibre fine-bran bread diet (22 g NDF/d)
Study: 6282302
Drug: Wholemeal bread
Normalized name: Wholemeal bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wholemeal bread diet (22 g NDF/d)
Study: 6282302
Drug: Coarse-bran bread
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coarse-bran bread diet (22 g NDF/d)
Study: 6282302
Drug: Low-fibre white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fibre white bread diet (9 g NDF/d)
Study: 31418933
Drug: Cornus mas
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cornus mas extract (CME) 300 mg, 3 capsules per day for 8 weeks
Study: 31418933
Drug: Starch powder,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch powder, 3 capsules per day for 8 weeks
Study: 28609534
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (3 mg/kg of elemental iron once daily for 12 weeks)
Study: 28609534
Drug: Iron polysaccharide
Normalized name: iron polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron polysaccharide complex (3 mg/kg of elemental iron once daily for 12 weeks)
Study: 26360834
Drug: Acamprosate calcium
Normalized name: Acamprosate Calcium
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acamprosate calcium tablets (multiple dosing)
Study: 26360834
Drug: Acamprosate calcium
Normalized name: Acamprosate Calcium
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acamprosate calcium tablets (single dosing under fasting conditions)
Study: 26360834
Drug: Acamprosate calcium
Normalized name: Acamprosate Calcium
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acamprosate calcium tablets (single dosing under fed conditions)
Study: 26360834
Drug: Acamprosate calcium
Normalized name: Acamprosate Calcium
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acamprosate calcium tablets (bioequivalence evaluation)
Study: 23642776
Drug: EVOO (50ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVOO (50ml daily)
Study: 14988895
Drug: gamma radiation
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma radiation treatment (gamma‐RT)
Study: 1406416
Drug: Cholestyramine 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 16 g/day
Study: 1406416
Drug: Pravastatin (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (long-term treatment)
Study: 1406416
Drug: Resin (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin (long-term treatment)
Study: 1406416
Drug: Pravastatin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (12 weeks monotherapy)
Study: 1406416
Drug: Resin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin (12 weeks monotherapy)
Study: 3970333
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam 0.25 mg/kg
Study: 3970333
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam 0.5 mg/kg
Study: 3970333
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of diazepam (0.25 mg/kg and 0.5 mg/kg)
Study: 3970333
Drug: Higher premedication
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher premedication dose (0.5 mg/kg)
Study: 29474292
Drug: Pessary removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pessary removal daily
Study: 29474292
Drug: Pessary removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pessary removal at least weekly
Study: 29474292
Drug: Pessary removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pessary removal less often than once weekly
Study: 27941661
Drug: Phosphorus supplementation
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphorus supplementation (500 mg)
Study: 24398943
Drug: Alcohol (BrAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (BrAC up to 0.6 g/kg for 15 minutes followed by 100 minutes exposure)
Study: 19069799
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment including physical factors (a constant magnetic field and negatively polarized phytoaeroions), soft‐tissue manual therapy, and dosed physical exercises.
Study: 12517681
Drug: Drug withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug withdrawal program
Study: 10799721
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (5 days per week)
Study: 1563806
Drug: Barbiturates (high-dose)
Normalized name: 5-allyl-5-(2-methylpropyl)barbituric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barbiturates (high-dose)
Study: 1563806
Drug: Barbiturates (low-dose)
Normalized name: 5-allyl-5-(2-methylpropyl)barbituric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barbiturates (low-dose)
Study: 371650
Drug: i.v. injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. injection of oxytocin 10 u
Study: 371650
Drug: continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous infusion of dilute oxytocin
Study: 21226679
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement (5 mg melatonin, 225 mg magnesium, and 11.25 mg zinc, mixed with 100 g of pear pulp)
Study: 21226679
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement (5 mg melatonin, magnesium, and zinc)
Study: 16620649
Drug: 1% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% silver sulfadiazine cream (Group B)
Study: 12732773
Drug: Mesna solution
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesna solution
Study: 9862770
Drug: Cocaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (10 mg/70 kg)
Study: 9862770
Drug: Cocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (20 mg/70 kg)
Study: 9862770
Drug: Cocaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (40 mg/70 kg)
Study: 9862770
Drug: Nicotine (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.75 mg/70 kg)
Study: 11160635
Drug: Nicotine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (1.5 mg/70 kg)
Study: 9862770
Drug: Nicotine (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (3.0 mg/70 kg)
Study: 2178488
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lidocaine i.v.
Study: 7203722
Drug: d,l‐oxyfedrine (Myofedrin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l‐oxyfedrine (Myofedrin)
Study: 7203722
Drug: l‐oxyfedrine (ildamen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐oxyfedrine (ildamen)
Study: 31443627
Drug: Pilates-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates-based exercise treatment (n = 148)
Study: 30141776
Drug: 3 monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 monthly sessions with booster 3 months later (Group 1)
Study: 27529709
Drug: Pneumatic broadband
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumatic broadband light (PBBL) plus adapalene gel 0.3%
Study: 27529709
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel 0.3% monotherapy
Study: 24619106
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate (600 mg)
Study: 24619106
Drug: Dairy products
Normalized name: Food - Dairy Products, Whey, Cow's Milk
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy products (600 mg)
Study: 20573799
Drug: Caffeine intake
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine intake (quintiles: 22, 135, 285, 402, and 656 mg/d)